
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp has demonstrated robust financial growth, highlighted by a 22% year-over-year increase in its burn care franchise, reaching $39.9 million in FY2024. The company has also seen significant expansion in its MACI product line, with revenue growing 21% year-over-year in the fourth quarter of FY2024, reflecting a three-year compound annual growth rate of 20.9%. Additionally, the anticipated launch of new products, alongside strategic salesforce expansion, is expected to drive continued revenue acceleration and profitability through 2025, positioning Vericel favorably in the biopharmaceutical market.
Bears say
Vericel Corp's stock outlook appears negatively impacted by several fundamental factors, including a decline in expected revenues for 2026 and a valuation multiple compression within the high-growth small and mid-cap sector. The company reported weaker-than-anticipated revenues for its products, with notable misses in both Epicel and NexoBrid sales, partly attributed to patient health issues and fewer grafts per patient. Additionally, the potential risks of recession, competitive dynamics impacting product uptake, and disruptions in the commercial launch of key products add to the uncertainty surrounding the company's financial performance.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares